This is the authors' abstract. We don't add key points for this paper.
The efficacy of telithromycin 800 mg once daily for 5 to 10 days (1 study comprised 5- or 7-day telithromycin) was evaluated in 8 phase III/IV studies in patients with mild to moderate community-acquired pneumonia caused by atypical/intracellular pathogens. Atypical/intracellular pathogens were identified by serology and/or polymerase chain reaction analysis of sputum. Clinical outcome was assessed at test of cure (days 17 to 24) in the per-protocol population. In total, 2289 patients received telithromycin, and 702 received comparators. Of these, 1925 (including 4.5% identified with atypical pathogens) and 540 (including 8.1% identified with atypical pathogens), respectively, were included in the analysis. The clinical success rate for telithromycin was 91.2% (1755/1925) overall and 94.4% (34/36), 97.3% (36/37), and 100% (13/13) for Chlamydophila (Chlamydia) pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila, respectively (vs. 90.7% [490/540], 94.7% [18/19], 90.9% [20/22], and 2/3, respectively, for pooled comparators). Telithromycin is clinically efficacious in patients with mild to moderate community-acquired pneumonia caused by atypical/intracellular pathogens.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Dunbar et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: